Melanocortin receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-06. Where a claim depends on a specific study, the study is described rather than over-claimed.
Semax binds to melanocortin receptors and is thought to influence neuronal survival and plasticity rather than to act through the adrenal axis. Laboratory work has shown increased expression of brain-derived neurotrophic factor and nerve growth factor in treated tissue. Changes in c-Fos, a marker of neuronal activation, have also been reported. Because the peptide is rapidly degraded by peptidases, its effects are generally attributed to downstream signaling cascades rather than to sustained receptor occupancy.
Published studies are dominated by animal models of stroke, ischemia, and cognitive impairment, with a smaller number of human trials conducted in Russia. Many of the human reports are small, single-center, and published in Russian-language journals, which limits independent scrutiny. Outcome measures vary between studies and often rely on clinician-rated scales rather than objective biomarkers. Systematic reviews have noted the methodological weaknesses and called for larger, preregistered trials before firm conclusions can be drawn.
Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.
Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.
| Property | Value | Notes |
|---|---|---|
| Appearance | White lyophilized powder | Typical for synthetic peptides |
| Solubility | Freely soluble in water | Also soluble in saline |
| Storage temperature | -20 C or below | Protect from repeated freeze-thaw |
| Analytical method | Reverse-phase HPLC | Confirms purity and identity |
| Common synonym | ACTH(4-10) analog | Reflects structural origin |
Lyophilized material is chemically stable for extended periods when kept dry, cold, and protected from light. The powder is hygroscopic, so vials should be warmed to room temperature before opening to reduce condensation on the contents. Once dissolved, the peptide is far less stable because peptide bonds are susceptible to hydrolysis and the methionine residue can oxidize. Solutions are typically aliquoted and held at 2-8 °C for short intervals or frozen for longer ones, and repeated freeze-thaw cycles should be avoided.
Routine characterization relies on reversed-phase high-performance liquid chromatography to establish purity and on mass spectrometry to confirm molecular identity. Electrospray ionization and matrix-assisted laser desorption ionization are both used for mass verification. Amino acid analysis and peptide mapping can detect sequence errors. Common impurities include truncated sequences, methionine sulfoxide formed by oxidation, and deamidated products. Chromatograms are usually recorded near 214 nm, where the peptide backbone absorbs, and purity is reported as the percentage area of the principal peak.
Verification of a supplied batch generally combines a certificate of analysis with independent testing, because certificates are self-reported documents. A typical package includes a chromatographic trace, a mass spectrum, and a stated water or counter-ion content. Batch-to-batch consistency matters more than a single purity figure when results are compared across experiments. No single mandatory standard governs research-grade peptide release, so laboratories are expected to define their own acceptance criteria. Residual trifluoroacetate from purification is a frequently overlooked counter-ion.
Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.
Published research on this peptide originates mainly from Russian laboratories, and the wider international literature is comparatively thin. Studies have used rodent models of stroke, hypoxia, and memory tasks, with a smaller number of human trials reported. Reported outcomes include changes in attention and memory measures, along with effects on neurotrophic factor expression in some experiments. Small sample sizes, inconsistent dosing protocols, and limited independent replication are widely noted limitations, so the strength of the clinical evidence remains an open question.
Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.
DFMDA, also known as F2-MDA or as 3,4-(difluoromethylenedioxy)amphetamine, is a chemical compound of the phenethylamine, amphetamine, and MDxx families related to the entactogen and psychedelic drug MDA. It is the derivative of MDA in which the two hydrogen atoms on the carbon atom of the 3,4-methylenedioxy ring have been replaced with fluorine atoms. Daniel Trachsel tested DFMDA in humans and found that it was inactive at doses of up to 250 mg orally. Higher doses were not tested. For comparison, he listed MDA's dose as 80 to 160 mg orally. DFMDA was active at the serotonin transporter (SERT) similarly to MDA and MDMA and with intermediate affinity between the two. It was developed with the aim of finding a non-neurotoxic drug able to be used as a less harmful substitute for entactogens such as MDMA. Since a major route of the normal metabolism of these compounds is scission of the methylenedioxy ring, producing neurotoxic metabolites such as α-methyldopamine, it was hoped that the difluoromethylenedioxy bioisostere would show increased metabolic stability and less toxicity. These compounds have not yet been tested in animals to verify whether they show similar pharmacological activity to the non-fluorinated parent compounds. It is also now generally accepted that MDMA neurotoxicity results from a variety of different causes and is not solely due to accumulation of α-methyldopamine, making it unclear how much less neurotoxic DFMDA and related drugs would be in practice. The chemical synthesis of DFMDA has been described.
==== Comparing molecular fingerprints ==== To search in a molecular structure database requires a metric to compare and score the molecular fingerprints. Tanimoto similarity (Jaccard index) is a commonly employed metric. A similarity value of 1 signifies identical fingerprints, while a value of 0 indicates structures that do not share any molecular properties. The calculated similarity value depends on the choice of fingerprint type. CSI:FingerID employs a logarithmic posterior probability to rank the structure candidates, where scores are represented as negative numbers, and zero is the optimum. This scoring function results in a higher number of correct identifications. Tanimoto similarities are also given.
== Contraindications == Like other non-selective beta blockers, levobunolol is contraindicated in patients with airway diseases such as asthma and severe chronic obstructive pulmonary disease (COPD), as well as heart problems such as sinus bradycardia, second- or third-degree atrioventricular block, sick sinus syndrome, and cardiogenic shock. Combination with MAO-A inhibitors is also contraindicated because it could cause a dangerous rise in blood pressure. Levobunolol is not useful for the treatment of closed-angle glaucoma.
== Deaths == 1 January – Frank McGarvey, Scottish footballer (St Mirren, Celtic, national team) (b. 1956) 18 March – Robert Lindsay, 29th Earl of Crawford, Scottish peer, MP (1955–1974) and Minister of State for Defence (1970–1972) (b. 1927) 21 March Willie Bell, Scottish footballer (Leeds United, national team) and manager (Birmingham City) (b. 1937) John Smith, Baron Kirkhill, Scottish peer, Lord Provost of Aberdeen (1971–1975) and Minister of State for Scotland (1975–1978) (b. 1930) 1 April – Ken Buchanan, professional boxer who became undisputed world lightweight champion in 1971 (b. 1945) 8 April – Bob Heatlie, Scottish songwriter ("Japanese Boy", "Cry Just a Little Bit", "Merry Christmas Everyone") and record producer (b. 1946). 30 April – Elizabeth Scott, Duchess of Buccleuch, wife of Richard Scott, 10th Duke of Buccleuch (b. 1954) 10 May – Hugo Burge, internet entrepreneur and owner of Marchmont House (b. 1972) 15 June – Gordon McQueen, Scottish footballer (Leeds United, Manchester United, national team) and manager. (b. 1953) 21 June – Winnie Ewing, Scottish politician (MP (1967–1979), MEP (1979–1999), MSP (1999–2003), President of the Scottish National Party (1987–2005)) (b. 1929) 26 June Craig Brown, Scottish professional footballer and football manager. (b. 1940) David Ogilvy, 13th Earl of Airlie, Scottish peer and Lord Chamberlain (1984–1997) (b. 1926) 2 July – Greig Oliver, 58, rugby union player. 6 September – John Cairney, Scottish actor (A Night to Remember, Cleopatra, Jason and the Argonauts), author and painter. (b.
Sources: en.wikipedia.org
== States == It was the individual states that formed the Federal Republic of Germany in 1949. This contrasted with post-war developments in Austria, where the national federation (Bund) was established first, and the individual states were subsequently defined as units within that federal framework. The German use of the term Länder ("lands") dates back to the Weimar Constitution of 1919. Previously, the states of the German Empire had been called Staaten ("states"). Today, it is common to use the term Bundesland (federated Land). Officially, the term "Bundesland" appears in neither the 1919 constitution nor the current one. Three Länder call themselves Freistaaten ("free states", an older German term for "republic"): Bavaria (since 1919), Saxony (originally from 1919 and again since 1990), and Thuringia (since 1994). Of the 17 states at the end of the Weimar Republic, six still exist (though partly with different borders):
=== Anti-inflammatory and analgesic agents === Glucocorticoids can be used in the short term and at the lowest dose possible for flare-ups and while waiting for slow-onset drugs to take effect. Combination of glucocorticoids and conventional therapy has shown a decrease in rate of erosion of bones. Steroids may be injected into affected joints during the initial period of RA, before the use of DMARDs or oral steroids. Non-NSAID drugs to relieve pain, like paracetamol may be used to help alleviate the pain symptoms; they do not change the underlying disease. The use of paracetamol may be associated with the risk of developing ulcers. NSAIDs reduce both pain and stiffness in those with RA but do not affect the underlying disease and appear to have no effect on people's long term disease course and thus are no longer first line agents. NSAIDs should be used with caution in those with gastrointestinal, cardiovascular, or kidney problems. Rofecoxib was withdrawn from the global market as its long-term use was associated to an increased risk of heart attacks and strokes. Use of methotrexate together with NSAIDs is safe, if adequate monitoring is done. COX-2 inhibitors, such as celecoxib, and NSAIDs are equally effective. A 2004 Cochrane review found that people preferred NSAIDs over paracetamol. However, it is yet to be clinically determined whether NSAIDs are more effective than paracetamol. The neuromodulator agents, topical capsaicin, may be reasonable to use in an attempt to reduce pain.
=== Pharmacokinetics === Peak levels of tavapadon are reached after approximately 2 to 4 hours with oral administration. It shows dose-proportional pharmacokinetics across its maintenance dosage range. Food does not significantly modify the pharmacokinetics of tavapadon and it can be taken without regard for food. The volume of distribution of tavapadon is 63.5 L. Its plasma protein binding is 93%, primarily to albumin. Tavapadon is primarily metabolized by CYP3A4. It has a major inactive metabolite. Unchanged tavapadon is excreted less than 1% in urine and feces. Its major inactive metabolite was excreted less than 5% in urine and feces. The elimination half-life of tavapadon is 25.5 hours.
Sources: en.wikipedia.org
It is associated with the melanocortin receptor family, particularly subtypes found in the central nervous system. This interaction is separate from the adrenal pathway activated by full-length ACTH.
Peptidases degrade the compound within minutes in circulation. This short half-life is one reason nasal delivery is used, placing the substance close to the olfactory and trigeminal pathways.
No large multicenter trials have been published in English-language journals. The existing human evidence consists mainly of smaller studies conducted in Russia, which limits generalization.
It originated at the Institute of Molecular Genetics in Moscow during the 1980s. The work was carried out by a Russian research group that specialized in peptide neuropharmacology.